Literature DB >> 7573017

Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis.

Q Qi1, M C Monier-Faugere, Z Geng, H H Malluche.   

Abstract

With the increasing occurrence of adynamic bone disease, it is essential to determine the level of bone turnover in chronically dialyzed patients before instituting vitamin D therapy. To assess the value of serum parathyroid hormone (PTH) levels for prediction of bone turnover, we determined sensitivity, specificity, and predictive value positive of serum PTH, alone or in combination with other variables, in 79 patients who underwent one or two bone biopsies. Serum PTH levels were determined by a radioimmunometric assay and were obtained at the time of bone biopsies. Patients were classified into (1) low or normal and (2) high bone turnover according to the value of activation frequency of bone. There were 57 biopsy specimens taken from hemodialysis patients and 39 specimens from continuous ambulatory peritoneal dialysis patients (CAPD). All patients with serum PTH levels within or below the normal range had low or normal bone turnover. Values of serum PTH above 450 pg/mL were 100% and 95.5% specific for high bone turnover in hemodialysis and CAPD patients, respectively. Values of serum PTH between 65 and 450 pg/mL had worse predictive value positive in CAPD patients (48.6% to 78.6%) than in hemodialysis patients (67.3% to 87.1%). When other characteristics of the patients were taken into consideration, only age in hemodialysis patients and serum ionized calcium in CAPD patients improved the predictive value of serum PTH. All hemodialysis patients younger than 45 years of age with serum PTH levels above 65 pg/mL (n = 15) had high bone turnover, and CAPD patients with low or normal bone turnover had higher serum ionized calcium. However, overall, bone turnover could not be predicted by serum PTH measurements in 30% of hemodialysis and 51.3% of CAPD patients. The data suggest that for patients with serum PTH levels between 65 and 450 pg/mL, bone biopsies are indicated to precisely assess bone turnover prior to initiation of vitamin D therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7573017     DOI: 10.1016/0272-6386(95)90599-5

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  31 in total

Review 1.  Renale osteodystrophie.

Authors:  Daniel Cejka
Journal:  Wien Med Wochenschr       Date:  2013-05-09

2.  Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study.

Authors:  Johann Herberth; Adam J Branscum; Hanna Mawad; Tom Cantor; Marie-Claude Monier-Faugere; Hartmut H Malluche
Journal:  Am J Kidney Dis       Date:  2010-03-27       Impact factor: 8.860

3.  Effect of haemodialysis on markers of bone turnover in children.

Authors:  Simon Waller; Deborah Ridout; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2007-01-10       Impact factor: 3.714

Review 4.  The role of bone biopsy for the diagnosis of renal osteodystrophy: a short overview and future perspectives.

Authors:  Catarina Carvalho; Catarina Moniz Alves; João Miguel Frazão
Journal:  J Nephrol       Date:  2016-07-29       Impact factor: 3.902

5.  Determinants of prevalent vertebral fractures and progressive bone loss in long-term hemodialysis patients.

Authors:  Jan Mares; Kristina Ohlidalova; Sylvie Opatrna; Jiri Ferda
Journal:  J Bone Miner Metab       Date:  2009-01-27       Impact factor: 2.626

6.  Calcium and phosphate balance in adolescents on home nocturnal haemodialysis.

Authors:  Daljit K Hothi; Elizabeth Harvey; Elizabeth Piva; Laura Keating; Donna Secker; Denis F Geary
Journal:  Pediatr Nephrol       Date:  2006-04-01       Impact factor: 3.714

7.  Matrix metalloproteinase-1 and -2 as markers of mineral bone disease in chronic kidney disease patients.

Authors:  K Thisiadou; V Liakopoulos; G Dimas; G Koliakos; M Karamouzis
Journal:  Hippokratia       Date:  2017 Jan-Mar       Impact factor: 0.471

8.  CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy.

Authors:  Feng-Xiang Yan; M Chris Langub; Mark A Ihnen; Carlton Hornung; Erkki Juronen; Mary K Rayens; Wei-Min Cai; Peter J Wedlund; Paolo Fanti
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

Review 9.  Role of bone biopsy in stages 3 to 4 chronic kidney disease.

Authors:  Anca Gal-Moscovici; Stuart M Sprague
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

10.  Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.

Authors:  Katherine Wesseling-Perry; Renata C Pereira; Hejing Wang; Robert M Elashoff; Shobha Sahney; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2008-12-02       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.